Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 19, 2010 - Issue 10
Submit an article Journal homepage
590
Views
28
CrossRef citations to date
0
Altmetric
Reviews

The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline

Christiaan H Vinkers University Medical Center Utrecht, Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, Heidelberglaan 100, 3584CX Utrecht, The Netherlands +31 0 30 253 1599; +31 0 30 253 7900; [email protected].; Utrecht University, Utrecht Institute for Pharmaceutical Sciences and Rudolf Magnus Institute of Neuroscience, Division of Pharmacology, Utrecht, The Netherlands
,
Naheed R Mirza NeuroSearch A/S, Department of Pharmacology, Ballerup, Denmark
,
Berend Olivier Utrecht University, Utrecht Institute for Pharmaceutical Sciences and Rudolf Magnus Institute of Neuroscience, Division of Pharmacology, Utrecht, The Netherlands; Yale University School of Medicine, Department of Psychiatry, New Haven, CT, USA
&
René S Kahn University Medical Center Utrecht, Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, Heidelberglaan 100, 3584CX Utrecht, The Netherlands +31 0 30 253 1599; +31 0 30 253 7900; [email protected].
Pages 1217-1233 | Published online: 03 Sep 2010

Citations (28)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Xufeng Yu, Zhan Gao, Mingzhou Gao & Mingqi Qiao. (2023) Bibliometric Analysis on GABA-A Receptors Research Based on CiteSpace and VOSviewer. Journal of Pain Research 16, pages 2101-2114.
Read now
Gabriella Guerrini & Giovanna Ciciani. (2013) Benzodiazepine receptor ligands: a patent review (2006 – 2012). Expert Opinion on Therapeutic Patents 23:7, pages 843-866.
Read now

Articles from other publishers (26)

Thomas D. Als, Mitja I. Kurki, Jakob Grove, Georgios Voloudakis, Karen Therrien, Elisa Tasanko, Trine Tollerup Nielsen, Joonas Naamanka, Kumar Veerapen, Daniel F. Levey, Jaroslav Bendl, Jonas Bybjerg-Grauholm, Biao Zeng, Ditte Demontis, Anders Rosengren, Georgios Athanasiadis, Marie Bækved-Hansen, Per Qvist, G. Bragi Walters, Thorgeir Thorgeirsson, Hreinn Stefánsson, Katherine L. Musliner, Veera M. Rajagopal, Leila Farajzadeh, Janne Thirstrup, Bjarni J. Vilhjálmsson, John J. McGrath, Manuel Mattheisen, Sandra Meier, Esben Agerbo, Kári Stefánsson, Merete Nordentoft, Thomas Werge, David M. Hougaard, Preben B. Mortensen, Murray B. Stein, Joel Gelernter, Iiris Hovatta, Panos Roussos, Mark J. Daly, Ole Mors, Aarno Palotie & Anders D. Børglum. (2023) Depression pathophysiology, risk prediction of recurrence and comorbid psychiatric disorders using genome-wide analyses. Nature Medicine 29:7, pages 1832-1844.
Crossref
Megan Snelleksz, Susan L Rossell, Andrew Gibbons, Jess Nithianantharajah & Brian Dean. (2022) Evidence that the frontal pole has a significant role in the pathophysiology of schizophrenia. Psychiatry Research 317, pages 114850.
Crossref
Dwipayan Bhattacharya, Aundrea F. Bartley, Qin Li & Lynn E. Dobrunz. (2022) Bicuculline restores frequency-dependent hippocampal I/E ratio and circuit function in PGC-1ɑ null mice. Neuroscience Research 184, pages 9-18.
Crossref
J.D. Ragland, R.J. Maddock, M.Y. Hurtado, C. Tanase, T.A. Lesh, T.A. Niendam, C.S. Carter & C. Ranganath. (2020) Disrupted GABAergic facilitation of working memory performance in people with schizophrenia. NeuroImage: Clinical 25, pages 102127.
Crossref
Sunpreet Kaur, Shamsher Singh, Anchal Arora, Parladh Ram, Sachin Kumar, Puneet Kumar & Sara Nidal Abed. 2020. Frontiers in Pharmacology of Neurotransmitters. Frontiers in Pharmacology of Neurotransmitters 241 292 .
Rémi Chaussenot, Muriel Amar, Philippe Fossier & Cyrille Vaillend. (2018) Dp71-Dystrophin Deficiency Alters Prefrontal Cortex Excitation-Inhibition Balance and Executive Functions. Molecular Neurobiology 56:4, pages 2670-2684.
Crossref
Werner Sieghart & Miroslav M. Savić. (2018) International Union of Basic and Clinical Pharmacology. CVI: GABA A Receptor Subtype- and Function-selective Ligands: Key Issues in Translation to Humans . Pharmacological Reviews 70:4, pages 836-878.
Crossref
Chloe E. Page & Laurence Coutellier. (2018) Reducing inhibition: A promising new strategy for the treatment of schizophrenia. EBioMedicine 35, pages 25-26.
Crossref
Meng-yi Xu & Albert H C Wong. (2018) GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia. Acta Pharmacologica Sinica 39:5, pages 733-753.
Crossref
Tobias Bast, Marie Pezze & Stephanie McGarrity. (2017) Cognitive deficits caused by prefrontal cortical and hippocampal neural disinhibition. British Journal of Pharmacology 174:19, pages 3211-3225.
Crossref
Rose Chesworth & Tim Karl. (2017) Molecular Basis of Cannabis-Induced Schizophrenia-Relevant Behaviours: Insights from Animal Models. Current Behavioral Neuroscience Reports 4:3, pages 254-279.
Crossref
Noor Alaudin Abdul WahabMohd. Normani ZakariaAbdul Hamid Abdul RahmanDinsuhaimi SidekSuzaily Wahab. (2017) Listening to Sentences in Noise: Revealing Binaural Hearing Challenges in Patients with Schizophrenia. Psychiatry Investigation 14:6, pages 786.
Crossref
Remmelt R. Schür, Luc W.R. Draisma, Jannie P. Wijnen, Marco P. Boks, Martijn G.J.C. Koevoets, Marian Joëls, Dennis W. Klomp, René S. Kahn & Christiaan H. Vinkers. (2016) Brain GABA levels across psychiatric disorders: A systematic literature review and meta-analysis of 1 H-MRS studies . Human Brain Mapping 37:9, pages 3337-3352.
Crossref
Iris E Sommer, Carrie E Bearden, Edwin van Dellen, Elemi J Breetvelt, Sasja N Duijff, Kim Maijer, Therese van Amelsvoort, Lieuwe de Haan, Raquel E Gur, Celso Arango, Covadonga M Díaz-Caneja, Christiaan H Vinkers & Jacob AS Vorstman. (2016) Early interventions in risk groups for schizophrenia: what are we waiting for?. npj Schizophrenia 2:1.
Crossref
Bruno P. Guiard & Giuseppe Di Giovanni. (2015) Central serotonin-2A (5-HT2A) receptor dysfunction in depression and epilepsy: the missing link?. Frontiers in Pharmacology 6.
Crossref
R S Kahn & I E Sommer. (2014) The neurobiology and treatment of first-episode schizophrenia. Molecular Psychiatry 20:1, pages 84-97.
Crossref
Scott E. Lukas. (2014) New perspectives on using brain imaging to study CNS stimulants. Neuropharmacology 87, pages 104-114.
Crossref
B.J. Morris & J.A. Pratt. (2014) Novel treatment strategies for schizophrenia from improved understanding of genetic risk. Clinical Genetics 86:5, pages 401-411.
Crossref
Nannan Guo, Kaichi Yoshizaki, Ryuichi Kimura, Fumikazu Suto, Yuchio Yanagawa & Noriko Osumi. (2013) A Sensitive Period for GABAergic Interneurons in the Dentate Gyrus in Modulating Sensorimotor Gating. The Journal of Neuroscience 33:15, pages 6691-6704.
Crossref
Gabriella Guerrini, Giovanna Ciciani, Annarella Costanzo, Simona Daniele, Claudia Martini, Carla Ghelardini, Lorenzo Di Cesare Mannelli & Samuele Ciattini. (2013) Synthesis of novel cognition enhancers with pyrazolo[5,1- c ][1,2,4]benzotriazine core acting at γ-aminobutyric acid type A (GABA A ) receptor. Bioorganic & Medicinal Chemistry 21:8, pages 2186-2198.
Crossref
Mathieu Verdurand, Stu G. Fillman, Cynthia Shannon Weickert & Katerina Zavitsanou. (2013) Increases in [3H]Muscimol and [3H]Flumazenil Binding in the Dorsolateral Prefrontal Cortex in Schizophrenia Are Linked to α4 and γ2S mRNA Levels Respectively. PLoS ONE 8:1, pages e52724.
Crossref
Jung Suk LeeJong Doo LeeHae-Jeong ParkMaeng-Keun OhJi Won ChunSe-Joo KimEosu KimJae-Jin Kim. (2013) Is the GABA System Related to the Social Competence Improvement Effect of Aripiprazole? An 18 F-Fluoroflumazenil PET Study . Psychiatry Investigation 10:1, pages 75.
Crossref
Mark J. Millan, Yves Agid, Martin Brüne, Edward T. Bullmore, Cameron S. Carter, Nicola S. Clayton, Richard Connor, Sabrina Davis, Bill Deakin, Robert J. DeRubeis, Bruno Dubois, Mark A. Geyer, Guy M. Goodwin, Philip Gorwood, Thérèse M. Jay, Marian Joëls, Isabelle M. Mansuy, Andreas Meyer-Lindenberg, Declan Murphy, Edmund Rolls, Bernd Saletu, Michael Spedding, John Sweeney, Miles Whittington & Larry J. Young. (2012) Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nature Reviews Drug Discovery 11:2, pages 141-168.
Crossref
Edmund T. Rolls. (2012) Glutamate, obsessive–compulsive disorder, schizophrenia, and the stability of cortical attractor neuronal networks. Pharmacology Biochemistry and Behavior 100:4, pages 736-751.
Crossref
Uwe Rudolph & Frédéric Knoflach. (2011) Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nature Reviews Drug Discovery 10:9, pages 685-697.
Crossref
George Capone. 2011. Neurocognitive Rehabilitation of Down Syndrome. Neurocognitive Rehabilitation of Down Syndrome 96 116 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.